Technology in Cancer Research & Treatment最新文献

{"title":"TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes.","authors":"Yuling Zhang, Hui Cao, Dongran Yu, Wanqi Feng, Shougen Cao, Yanbing Zhou, Ken S Lau, Zequn Li","doi":"10.1177/15330338261461720","DOIUrl":"10.1177/15330338261461720","url":null,"abstract":"<p><p>TIPE3, encoded by the human <i>TNFAIP8L3</i> gene, is a member of the TNFAIP8 family of lipid second-messenger transfer proteins that connects phosphoinositide signaling with cancer progression, therapeutic resistance, and clinical outcomes. Unlike other TIPE-family members primarily involved in immune regulation or apoptosis, TIPE3 directly transfers phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3) and modulates the PI3K/AKT, MEK/ERK, Wnt/β-catenin, NF-κB, Hedgehog, and mitochondrial stress pathways. Current evidence indicates that TIPE3 generally facilitates tumor growth, invasion, immune remodeling, autophagy, and platinum resistance across various malignancies, including lung, breast, pancreatic, gastric, colorectal, ovarian, cervical cancers, glioblastoma, and acute myeloid leukemia, whereas it may exhibit tumor-suppressive effects in specific contexts, such as head and neck squamous cell carcinoma. This review emphasizes three key concepts: pan-cancer functional duality, localization- and epigenetic-dependent regulation, and TIPE3-guided therapeutic stratification. We also examine conflicting findings, particularly in colorectal cancer, where disparities in mRNA versus protein assessment, tumor composition, immune contexture, subcellular localization, and treatment exposure may contribute to inconsistent prognostic associations. Finally, we propose a translational framework that integrates standardized detection, localization-aware pathology, multi-omics profiling, organoid and patient-derived xenograft validation, AI-assisted inhibitor discovery, RNA-based delivery, and rational combination therapy. Although no TIPE3-targeted therapies have yet reached clinical application, emerging mechanistic and drug discovery studies underscore TIPE3's potential as a valuable biomarker and therapeutic target in precision oncology.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261461720"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13272982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148259720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients.","authors":"Xiaoyi Wang, Qingyun Zhang, Yecheng Xu, Wenteng Miao, Bai'an Tao, Chen Jin, Deliang Fu","doi":"10.1177/15330338261469099","DOIUrl":"10.1177/15330338261469099","url":null,"abstract":"<p><p>IntroductionA subgroup of pancreatic cancer with unstable genome, such as BRCA mutation, may be more sensitive to platinum-based chemotherapy. How to define the patients with homologous recombination deficiency (HRD) status other than BRCA mutation has been a clinical challenge and interest.MethodsIn this retrospective cohort study, we collected NGS data of 163 pancreatic cancer patients from July 2020 to April 2024. HRD score was calculated by 3DMed-HRD algorithm. The median of HRD score of our study population was used as potential cut-off value to determine HRD status. Cox regression was used to evaluate association of HRD status, platinum-based chemotherapy and overall survival (OS). Kaplan-Meier method with log-rank test was performed to analyze OS among different subgroups.ResultsAmong the 163 patients, the HRD score ranged from 0 to 76. The mean value was 10.48. The median was 6. With a criterion of HRD ≥6 and/or germline Homologous Recombination Repair (HRR) mutation, a total of 89 patients were considered to be HRD+. HRD+ status was associated with a poor prognosis (HR: 1.46, 95%CI:1.01-2.11, p=0.04). Platinum-based all-time usage would reduce the hazard of death by 34% (HR: 0.66, 95%CI: 0.45-0.97, p=0.03). Among the HRD+ subjects, the initiation of platinum-based chemotherapy might be associated with a longer overall survival (OS: 19.92 vs 15.38, Log-Rank test, p=0.09).ConclusionHRD score could be a potential indicator for genome unstable pancreatic cancer patients who would benefit from platinum derivatives. Future study with better design and larger population size would help to determine a proper threshold for clinical application.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261469099"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13369404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phantom-Based Dosimetric Comparison of Helical and Fixed-Beam TomoTherapy for Spatially Fractionated Radiotherapy Using GRID and Lattice Target Designs.","authors":"Narakorn Sihawong, Wannapha Nobnop, Imjai Chitapanarux, Anirut Watcharawipha, Akanit Chaiyapong","doi":"10.1177/15330338261444832","DOIUrl":"10.1177/15330338261444832","url":null,"abstract":"<p><p>IntroductionSpatially Fractionated Radiotherapy (SFRT) delivers intentionally heterogeneous dose distributions with alternating high- and low-dose regions and has been widely applied in the management of bulky tumors. In SFRT, high-dose sub-volumes (referred to as vertices) are distributed within the gross tumor volume (GTV) to create a spatial peak-valley dose pattern. However, studies of SFRT using the TomoTherapy platform remain limited. This study evaluates the dosimetric performance of GRID and lattice vertex designs using TomoHelical and TomoDirect techniques.MethodsA phantom-based planning study was performed with two simulated GTV representing medium- and large-sized tumors. Cylindrical GRID vertices and spherical lattice vertices were created with diameters of 1.00 cm and 1.25 cm and corresponding center-to-center spacings of 3.0 cm and 2.5 cm, respectively. Treatment plans were created using TomoHelical and TomoDirect techniques with identical prescription criteria, requiring at least 50% of the target volume to receive 15 Gy in a single fraction. Beam-on time, normal tissue dose metrics (V30% and V50%), homogeneity index, conformity index, peak-to-edge dose ratio (PEDR), and peak-to-valley dose ratio (PVDR) were evaluated. Delivery accuracy was assessed using ArcCHECK measurements with a 3%/2 mm gamma criterion.ResultsAll plans met prescription and delivery accuracy requirements, with gamma passing rates exceeding 95%. TomoHelical produced higher PVDR and PEDR values, improved conformity, and lower V50% compared with TomoDirect. TomoDirect achieved shorter beam-on times but showed greater variability in vertex mean dose. Lattice configurations yielded higher PVDR values than GRID, while vertex diameter had minimal impact on most dosimetric parameters.ConclusionTomoHelical delivery combined with lattice designs provided superior dose modulation and normal tissue sparing for SFRT, while requiring longer delivery times. In contrast, GRID designs enabled faster treatment delivery. These findings provide practical guidance for optimizing SFRT planning using the TomoTherapy platform.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261444832"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Surface Guidance Versus Laser Alignment for Precision Lung Cancer Particle Therapy.","authors":"Xiyu Zhang, Yuze Yang, Jingfang Mao, Yinxiangzi Sheng","doi":"10.1177/15330338261425319","DOIUrl":"10.1177/15330338261425319","url":null,"abstract":"<p><p>IntroductionLung particle therapy using pencil beam scanning achieves high dose conformity but remains vulnerable to geometric uncertainties from suboptimal initial setup. Surface-guided radiotherapy (SGRT) improves setup reproducibility in photon workflows, yet evidence in lung particle therapy remains limited. This study evaluates the clinical value of SGRT in improving six degrees of freedom (6-DOF) setup reproducibility in lung cancer particle therapy.MethodsThis retrospective cohort study analyzed 63 lung cancer patients receiving 1277 treatment fractions at our center from February 2023 to January 2024. Comparisons were made between conventional laser-based positioning, which included 983 fractions, and SGRT workflows, which included 294 fractions. Following patient positioning, therapists manually registered orthogonal kilovoltage (kV) x-ray images with planning digitally reconstructed radiographs (DRRs) to calculate 6-DOF correction parameters, including translational (lateral, longitudinal, vertical) and rotational (pitch, roll, yaw) components, and to quantify the pre-correction setup error . Absolute 6-DOF displacements and three-dimensional vector magnitudes (MAG) were measured. The analysis included 36 supine patients with 739 treatment fractions and 27 prone patients with 538 fractions.ResultsThe SGRT group exhibited statistically significant reductions in median shifts for lateral (0.25 cm to 0.21 cm, <i>p</i> = 0.021), longitudinal (0.25 cm to 0.21 cm, <i>p</i> = 0.014), pitch (1.0° to 0.8°, <i>p</i> = 0.001), and MAG (0.59 cm to 0.53 cm, <i>p</i> = 0.002) compared to conventional methods. These improvements in median values were more pronounced in supine-positioned patients, while no significant differences were observed in prone-positioned patients. Furthermore, substantial reductions were achieved in ninth decile deviations (1.09 cm to 1.03 cm), and the third quartile deviations (0.83 cm to 0.74 cm) in the overall cohort.ConclusionSGRT enhances setup precision for proton and carbon ion lung cancer radiotherapy, reduces pre-correction setup error, and provides clinical support for patient setup reproducibility.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261425319"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urine IRF4/PENK/PXDN Methylation Signatures Enable Machine Learning-Driven Bladder Cancer Detection and Microenvironment Dissection.","authors":"Yi He, Wenhua Xie, Wei Chen, Shengjie Dai, Xintao Wang, Xiaokai Zhao, Siyu Lei, Wei Zhu, Yi Qian, Jinpeng Feng, Ziying Gong, Jieyi Li, Pengmin Yang, Xinyu Xu, Wenjie Fei, Daoyun Zhang, Yifang Cao, Jing Jin","doi":"10.1177/15330338261453486","DOIUrl":"10.1177/15330338261453486","url":null,"abstract":"<p><p>IntroductionCystoscopy-based diagnosis and surveillance of bladder cancer (BC) remain challenging. This study presents a urine-based assay that enriches DNA-methylation signals via PCR enrichment and applies a machine-learning model to enable cost-effective early detection.MethodsIn a prospective cohort at hospital (May 2022-November 2023), 155 individuals were enrolled, BC was diagnosed and confirmed by cystoscopy-guided biopsy and histopathology. Targeted next-generation sequencing of urine DNA quantified methylation at 44 CpG sites within IRF4, PENK and PXDN. Supervised classifiers trained on these features distinguished tumor from non-tumor urine samples. Systems analyses around IRF4/PENK/PXDN mapped signaling pathways, protein interaction modules and tumor-microenvironment contexts in BC.ResultsUsing 155 urine samples (68 BC, 87 non-BC) with methylation and transcript expression data in TCGA-BLCA, we found significantly increased methylation of IRF4, PENK, and PXDN in BC (P < 0.0001). Corresponding mRNA levels of IRF4 and PENK were significantly downregulated in tumor tissues, with PXDN showing a declining trend. Methylation of IRF4 and PXDN negatively correlated with their expression (P < 0.0001). A 41-CpG-site random forest classifier targeting IRF4, PENK, and PXND (BladderCando model) demonstrated excellent performance in distinguishing BC from non-BC individuals (AUC = 0.9783, F1 = 0.9773), outperforming urine cytology for low-grade BC detection. Co-expression and enrichment analyses identified DCN as a central hub gene, primarily linked to ECM functions. High expression of PXDN, IRF4, and DCN correlated with upregulated immune checkpoint genes and increased immune cell infiltration. Single-cell sequencing revealed PXDN in fibroblasts and endothelial cells, DCN in fibroblasts, and IRF4 in T cells, with expression patterns in urine mirroring tumor tissue profiles.ConclusionThis study establishes IRF4, PENK and PXDN methylation in urine as robust molecular signatures for BC detection, with machine-learning integration markedly enhancing diagnostic precision. Beyond early surveillance, these epigenetic alterations delineate tumor-microenvironment interactions that may inform future therapeutic strategies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261453486"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13260975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148228360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models.","authors":"Esther Frimpong, Raviteja Bulusu, Joy Okoro, Xue Zhu, Joshua Ablordeppey, Bo Han, Saunjoo Yoon, Edward Agyare","doi":"10.1177/15330338261468414","DOIUrl":"10.1177/15330338261468414","url":null,"abstract":"<p><p>IntroductionDysregulated epidermal growth factor receptor (EGFR) signaling is a key mechanism driving cancer progression and metastasis. Owing to its frequent overexpression in pancreatic cancer (PCa), EGFR has become a desirable molecular target for targeted therapies. XYZ-I-73 (N-(5-fluoro-2-oxo-1-(tetrahydrofuran-2-yl)-1,2-dihydropyrimidin-4-yl) dodecanamide), a structural analog of 5-fluorouracil (5-FU), has been previously synthesized and shown to exhibit cytotoxicity against PCa cells.MethodsXYZ-I-73 was entrapped in liposomes via thin-film hydration and subsequently conjugated to EGFR antibodies to produce an immunoliposome formulation- Ab-XYZ-I-73LnP (where 'Ab' denotes antibody-conjugated and 'LnP' denotes liposomal nanoparticle). In vitro efficacy was assessed by measuring cell viability and apoptosis in MiaPaCa-2 and PANC-1 cells, while pharmacokinetics and antitumor efficacy were determined in a cell line-derived xenograft (CDX) mouse model.ResultsAb-XYZ-I-73LnP exhibited a mean particle size of 143nm ± 2.3, PDI (0.37), and zeta potential -46.2 ± 1.3mV. In MiaPaCa-2 cells, Ab-XYZ-I-73LnP showed remarkably higher cytotoxicity than 5-FU in both 2D (IC₅₀ = 2.5 ± 0.9μM vs 13.2 ± 1.1μM) and 3D cultures (IC₅₀ = 8.1 ± 1.1μM vs 26.7 ± 1.1 μM). Similarly, in PANC-1 cells, Ab-XYZ-I-73LnP showed lower IC₅₀ values compared to 5-FU;2D (IC₅₀ = 2.9 ±1.1 μM vs 20.4±1.2 μM), 3D (IC₅₀ = 12.9 ± 0.6μΜ vs 37.1±0.9 μM). Pharmacokinetic analysis revealed a prolonged half-life for Ab-XYZ-I-73LnP compared with free 5-FU (t1/2 = 1.62 ± 0.03 h vs 0.49 ± 0.01 h, p < 0.001). There was about a 2-fold increase in the area under the curve (AUC) for Ab-XYZ-I-73LnP compared to 5-FU (AUC= 0.32 ± 0.04µg/(L*hr) vs 0.15 ± 0.02µg/(L*hr), p<0.01).ConclusionOverall, the study supports the formulation of an immunoliposome of modified 5-FU, which may significantly enhance drug bioavailability and therapeutic potential for the treatment of PCa.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261468414"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Therapy and Immune Preservation: Dosimetric Rationale, Clinical Evidence, and Implications for the Immunotherapy Era.","authors":"Austin D Thompson, Michael J MacFarlane, Samuel Rosner, Matthew J Ferris","doi":"10.1177/15330338261495917","DOIUrl":"https://doi.org/10.1177/15330338261495917","url":null,"abstract":"<p><p>Radiation-induced lymphopenia (RIL) is a clinically significant and potentially modifiable consequence of radiotherapy, independently associated with worse survival and attenuated immunotherapy efficacy across multiple disease sites. Its mechanistic basis lies in the exquisite radiosensitivity of circulating lymphocytes and the irradiation of hematopoietically active bone marrow and lymphatic structures within and adjacent to standard treatment fields. Proton therapy, through its fixed beam angles and lack of exit dose by virtue of the Bragg peak phenomenon, delivers substantially less integral dose to surrounding normal tissues, reducing cumulative radiation exposure to the circulating immune compartment. This dosimetric advantage translates into meaningfully lower rates of severe RIL in lung, esophageal, brain, and head and neck cancers. The effective dose to immune cells (EDIC) - a composite metric integrating mean heart dose, mean lung dose, and mean body dose to estimate cumulative lymphocyte irradiation over a treatment course - and the effective dose to immune cells, radiotherapy course-adjusted (EDRIC), have been validated as dosimetric predictors of RIL severity and as independent predictors of progression-free survival in stage III non-small cell lung cancer (NSCLC) patients receiving consolidative durvalumab. In an era defined by the widespread integration of immune checkpoint inhibitors (ICI) into radiotherapy-based regimens, preservation of immune competence during treatment has direct therapeutic implications. This review synthesizes mechanistic, dosimetric, and clinical evidence supporting the role of proton therapy in immune sparing, with emphasis on emerging randomized data and actionable treatment planning strategies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261495917"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrapancreatic Fat Deposition and Prostate Cancer Risk: A Primary Case-Control Study.","authors":"Hui Wang, Hui Li, Kui Zhang, Lingfeng Wu, Chao Wang, Daocheng Fang, Yufei Yu, Xinming Yang, Shuangquan Sun, Xiao Chen, Shumei Bi, Hui Wen","doi":"10.1177/15330338261500542","DOIUrl":"https://doi.org/10.1177/15330338261500542","url":null,"abstract":"<p><p>IntroductionVisceral fat is associated with cancer risk. Intrapancreatic fat deposition (IPFD) has been associated with pancreatic diseases, but its role in extra-pancreatic malignancies remains unclear. This case-control study aimed to investigate the association between IPFD and prostate cancer risk.MethodsA total of 143 patients with newly diagnosed, treatment-naïve prostate cancer and 286 age-matched controls without malignancy were enrolled in this retrospective study. IPFD was assessed using unenhanced computed tomography (CT) by two markers: pancreatic CT attenuation (PanCT) and pancreatic-to-spleen attenuation ratio (P/S). Multivariable logistic regression was performed to evaluate the association between IPFD and prostate cancer risk, with sequential adjustment for demographic, metabolic, and hepatic parameters.ResultsThe risk of prostate cancer decreases as PanCT (p < 0.01) and P/S increases (p = 0.05). Participants with prostate cancer had lower pancreatic CT attenuation compared to controls. In fully adjusted models, higher PanCT quartiles were associated with progressively lower odds of prostate cancer (Q2: OR 0.32, 95% CI 0.15-0.69; Q3: OR 0.21, 95% CI 0.08-0.52; Q4: OR 0.11, 95% CI 0.04-0.29; all p < 0.01). Similar inverse associations were observed for P/S ratio quartiles (Q3: OR 0.30, 95% CI 0.13-0.68; Q4: OR 0.31, 95% CI 0.13-0.75).ConclusionIntrapancreatic fat deposition is independently associated with an increased risk of prostate cancer, regardless of hepatic fat and body mass index.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261500542"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T Cell Therapy in Solid Tumors: Implications of Satri-cel for Gastric and Gastrointestinal Cancers.","authors":"George Laliotis, Anwaar Saeed","doi":"10.1177/15330338261499846","DOIUrl":"https://doi.org/10.1177/15330338261499846","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261499846"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: FGF23 is a potential prognostic biomarker in uterine sarcoma.","authors":"","doi":"10.1177/15330338261417025","DOIUrl":"10.1177/15330338261417025","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261417025"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}